HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications

Cited by (477)

Items 101–200 of 477

1. The HAT/HDAC interplay: Multilevel control of STAT signaling
   Laura Icardi, Karolien De Bosscher, Jan H. Tavernier · 2012 · Cytokine & Growth Factor Reviews
2. Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma
   Maria J. Williams, William Singleton, Stephen P. Lowis, Karim T. A. Malik, Kathreena Mary Kurian · 2017 · Frontiers in Oncology
3. The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair
   Yun Dai, Shuang Chen, Maciej Kmieciak, Liang Zhou, Hui‐Yi Lin, Xin‐Yan Pei, Steven Grant · 2013 · Molecular Cancer Therapeutics
4. ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview
   E. Arrigoni, Sara Galimberti, Mario Petrini, Romano Danesi, Antonello Di Paolo · 2016 · Expert Opinion on Drug Metabolism & Toxicology
5. Histone Deacetylase Classes I and II Regulate Kaposi's Sarcoma-Associated Herpesvirus Reactivation
   Hye Jin Shin, Jennifer DeCotiis, Mario Giron, Diana Palmeri, David M. Lukac · 2013 · Journal of Virology
6. Inactivating histone deacetylase HDA promotes longevity by mobilizing trehalose metabolism
   Ruofan Yu, Xiaohua Cao, Luyang Sun, Jun‐yi Zhu, Brian M. Wasko, Wei Liu, Emeline Crutcher, Haiying Liu, Myeong Chan Jo, Lidong Qin et al. · 2021 · Nature Communications
7. Suberoylanilide hydroxamic acid (SAHA) reverses chemoresistance in head and neck cancer cells by targeting cancer stem cells via the downregulation of nanog
   Bhavna Kumar, Arti Yadav, James C. Lang, Theodoros Nicholas Teknos, Pawan Kumar · 2015 · Genes & Cancer
8. Clinical use and applications of histone deacetylase inhibitors in multiple myeloma
   Shaji Kunnathu Kumar, Nidhi Tandon, Vijay G. Ramakrishnan · 2016 · Clinical Pharmacology Advances and Applications
9. Epigenetics and Oncology
   Padmaja Mummaneni, Stacy Shifflett Shord · 2014 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
10. Is Glioblastoma an Epigenetic Malignancy?
    Marta Maleszewska, Bozena Kaminska · 2013 · Cancers
11. Regulating Chromatin by Histone Acetylation
    Anne‐Lise Steunou, Dorine Rossetto, Jacques Côté · 2013 · Springer eBooks
12. Perspectives on natural product epigenetic modulators in chemical biology and medicine
    Fanny Cherblanc, Robert W. M. Davidson, Paolo Di Fruscia, Nitipol Srimongkolpithak, Matthew John Fuchter · 2013 · Natural Product Reports
13. Epigenetic drugs against cancer: an evolving landscape
    Antonella Di Costanzo, Nunzio Del Gaudio, Antimo Migliaccio, Lucia Altucci · 2014 · Archives of Toxicology
14. Curcumin, a potential therapeutic candidate for retinal diseases
    Leilei Wang, Yue Sun, Kun Huang, Ling Zheng · 2013 · Molecular Nutrition & Food Research
15. Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
    K. Maes, E. Menu, E. Van Valckenborgh, I. Van Riet, K. Vanderkerken, E. De Bruyne · 2013 · Cancers
16. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma
    Paul Gerard Guy Richardson, Constantine S. Mitsiades, Jacob P. Laubach, Roman Hájek, Ivan Špıčka, Meletios Athanasios Dimopoulos, Philippe Moreau, David Samuel DiCapua Siegel, Sundar Jagannath, Kenneth Carl Anderson · 2013 · Leukemia Research
17. Selective inhibition of histone deacetylase 3 by novel hydrazide based small molecules as therapeutic intervention for the treatment of cancer
    Sravani Pulya, Tarun Kumar Patel, Milan Paul, Nilanjan Adhikari, Suvankar Banerjee, Ganesh Routholla, Swati Biswas, Tarun Jha, Balaram Ghosh · 2022 · European Journal of Medicinal Chemistry
18. Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia
    Zainul S. Hasanali, Bikramajit Singh Saroya, August Stuart, Sara Shimko, Juanita J. Evans, Mithun Vinod Shah, Kamal Sharma, Violetta V. Leshchenko, Samir Sunil Parekh, Thomas P. Loughran et al. · 2015 · Science Translational Medicine
19. Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine
    Maria Cosenza, Monica Civallero, Luigi Marcheselli, Stefano Sacchi, Samantha Pozzi · 2017 · APOPTOSIS
20. Manipulating macrophage polarization and function using classical HDAC inhibitors: Implications for autoimmunity and inflammation
    Asadollah Mohammadi, Atefeh Sharifi, Reza Pourpaknia, Saeed Mohammadian Haftcheshmeh, Amirhossein Sahebkar · 2018 · Critical Reviews in Oncology/Hematology
21. Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival
    Constantinos Giaginis, Christos Damaskos, Ioannis S. Koutsounas, Adamantia Zizi‐Serbetzoglou, Nicolaos Tsoukalas, Efstratios Patsouris, Gregorios P. Kouraklis, Stamatios E Theocharis · 2015 · BMC Gastroenterology
22. Suberoylanilide hydroxamic acid (SAHA) promotes the epithelial mesenchymal transition of triple negative breast cancer cells via HDAC8/FOXA1 signals
    Shao Wu, Zhi Luo, P.Y. Yu, Hui Xie, Yuwen He · 2015 · Biological Chemistry
23. Targeted Therapy for Medullary Thyroid Cancer: A Review
    S. R. Priya, Chandra Shekhar Dravid, Raghunadharao Digumarti, Mitali Dandekar · 2017 · Frontiers in Oncology
24. Preclinical evaluation and molecular docking of 1,3-benzodioxole propargyl ether derivatives as novel inhibitor for combating the histone deacetylase enzyme in cancer
    Neeraj Kumar, Ravi Tomar, Apurva Kumari Pandey, Vartika Tomar, Vimal Kishor Singh, Ramesh Chandra · 2017 · Artificial Cells Nanomedicine and Biotechnology
25. Panobinostat for the treatment of multiple myeloma: the evidence to date
    Sunil Sharma, Hanna Bailey, David Dean Stenehjem · 2015 · Journal of Blood Medicine
26. Histone deacetylase inhibitor‐mediated cell death is distinct from its global effect on chromatin
    Victoria L. Luchenko, Thomas Litman, Arup R. Chakraborty, Aaron Heffner, Christopher B. Devor, Julia Wilkerson, Wilfred Donald Stein, Robert W. Robey, Lois Bangiolo, David Levens et al. · 2014 · Molecular Oncology
27. Chemical Inhibitors of Epigenetic Methyllysine Reader Proteins
    Natalia Milosevich, Fraser A. Hof · 2015 · Biochemistry
28. Down-regulation of histone deacetylase 4, −5 and −6 as a mechanism of synergistic enhancement of apoptosis in human lung cancer cells treated with the combination of a synthetic retinoid, Am80 and green tea catechin
    Yukiko Oya, Anupom Mondal, Anchalee Rawangkan, Sonthaya Umsumarng, Keisuke Iida, Tatsuro Watanabe, Miki Kanno, Kaori Suzuki, Zhenghao Li, Hiroyuki Kagechika et al. · 2017 · The Journal of Nutritional Biochemistry
29. A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma
    Theodoros Nicholas Teknos, J.C. Grecula, Amit Agrawal, Matthew Owen Old, E. Ozer, R. Carrau, Seok-Young Kang, James William Rocco, Dukagjin M. Blakaj, V.M. Diavolitsis et al. · 2018 · Investigational New Drugs
30. Alteration of MDM2 by the Small Molecule YF438 Exerts Antitumor Effects in Triple-Negative Breast Cancer
    Peipei Shan, Feifei Yang, Hongzhao Qi, Yunjie Hu, Sujie Zhu, Zhenqing Sun, Zhe Zhang, Chuanxiao Wang, Caixia Hou, Jie Yu et al. · 2021 · Cancer Research
31. Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway
    Liu, Qingqing, Zhang, Bin, Wang, Yuanjiang, Wang, Xinyi, Gou, Shaohua · 2022 · European Journal of Medicinal Chemistry
32. Histone modifications: Targeting head and neck cancer stem cells
    John Minh Le · 2014 · World Journal of Stem Cells
33. Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma
    Geoffrey M. Matthews, Marcus Lefebure, Maria Doyle, Jake Shortt, Jason Ellul, Marta Chesi, Kellie-Marie Banks, Eva Vidacs, D Faulkner, Peter Wisdom Atadja et al. · 2013 · Cell Death and Disease
34. HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy
    Haishan Zhao, Zhaojin Yu, Lin Zhao, Miao He, Jie Ren, Huizhe Wu, Qiuchen Chen, Weifan Yao, Minjie Wei · 2016 · Japanese Journal of Clinical Oncology
35. Novel immune modulators used in hematology: impact on NK cells
    Stephanie Krieg, Evelyn Ullrich · 2013 · Frontiers in Immunology
36. ST7612AA1, a Thioacetate-ω(γ-lactam carboxamide) Derivative Selected from a Novel Generation of Oral HDAC Inhibitors
    Giuseppe Giannini, Loredana Vesci, Gianfranco Battistuzzi, Davide Vignola, Ferdinando Maria Milazzo, Mario Berardino Guglielmi, Marcella Barbarino, M. Santaniello, Nicola Fantò, Marco Mor et al. · 2014 · Journal of Medicinal Chemistry
37. Histone deacetylase inhibitor valproic acid (VPA) promotes the epithelial mesenchymal transition of colorectal cancer cells via up regulation of Snail
    Ju-Tao Feng, Cen Junhua, Jun Li, Rujin Zhao, Canhua Zhu, Zongxin Wang, Jiafen Xie, Wei Tang · 2015 · Cell Adhesion & Migration
38. New treatments for autosomal dominant polycystic kidney disease
    Ming‐Yang Chang, Albert C.M. Ong · 2013 · British Journal of Clinical Pharmacology
39. Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions
    Constantinos Giaginis, Paraskevi Th. Alexandrou, Ioanna Kassiani Delladetsima, Ioanna Giannopoulou, Efstratios Patsouris, Stamatios E Theocharis · 2013 · Tumor Biology
40. Small-molecular modulators of cancer-associated epigenetic mechanisms
    Yukihiro Itoh, Takayoshi Suzuki, Naoki Miyata · 2013 · Molecular BioSystems
41. HDAC1 and HDAC2 collectively regulate intestinal stem cell homeostasis
    Cheryl Doreen Zimberlin, Cesare Lancini, Rachel Sno, Sanne L. Rosekrans, Chelsea M. McLean, Hanneke Vlaming, Gijs R. VAN DEN BRINK, Michael L Bots, Jan Paul Medema, Jan‐Hermen Dannenberg · 2015 · The FASEB Journal
42. Histone Deacetylase Inhibitors Antagonize Distinct Pathways to Suppress Tumorigenesis of Embryonal Rhabdomyosarcoma
    Terra Vleeshouwer-Neumann, Michael Phelps, Theo K. Bammler, James W. MacDonald, Isaac Jenkins, Eleanor Y. Chen · 2015 · PLoS ONE
43. Anti-breast cancer effects of histone deacetylase inhibitors and calpain inhibitor.
    Megan A Mataga, Shoshana Rosenthal, Sarah Heerboth, Amrita Devalapalli, Shannon Kokolus, Leah R Evans, Mckenna M. Longacre, Genevieve Housman, Sibaji Sarkar · 2012 · PubMed
44. Downregulation of HDAC9 inhibits cell proliferation and tumor formation by inducing cell cycle arrest in retinoblastoma
    Yiting Zhang, Dan Wu, Fengjie Xia, Hongyu Xian, Xinyue Zhu, Hongjuan Cui, Zhenping Huang · 2016 · Biochemical and Biophysical Research Communications
45. Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy
    Ana Vanessa Nascimento, Hassan Bousbaa, Domingos Ferreira, Bruno Filipe Carmelino Cardoso Sarmento · 2015 · Current Drug Targets
46. The Anti-Tumor Effect of HDAC Inhibition in a Human Pancreas Cancer Model Is Significantly Improved by the Simultaneous Inhibition of Cyclooxygenase 2
    Olivier Peulen, Arnaud Gonzalez, Paul Peixoto, Andrei Turtoï, Denis Mottet, Philippe Delvenne, Vincent Castronovo · 2013 · PLoS ONE
47. Valproic acid inhibits the growth of HeLa cervical cancer cells via caspase-dependent apoptosis
    Bo Han, Bo Ra You, Woo Hyun Park · 2013 · Oncology Reports
48. Epithelial–mesenchymal transition in pancreatic cancer: Is it a clinically significant factor?
    Jia-Hao Jiang, Chen Liu, He Cheng, Lu Yu, Yi Qin, Yong-Feng Xu, Jin Xu, Jiang Long, Liang Liu, Quan-Xing Ni et al. · 2014 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
49. Efficient Delivery and Replication of Oncolytic Virus for Successful Treatment of Head and Neck Cancer
    Masakazu Hamada, Yoshiaki Yura · 2020 · International Journal of Molecular Sciences
50. Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia
    Siddha N. Kasar, Chingiz Underbayev, Y Yuan, Matt Hanlon, Sameh Samir Saad Aly, Hina Khan, Victor Tsu-Shih Chang, Mona Batish, T Gavrilova, Fatu Badiane Markey et al. · 2013 · Oncogene
51. The Desmosomal Protein Desmoglein 1 Aids Recovery of Epidermal Differentiation after Acute UV Light Exposure
    Jodi L. Johnson, Jennifer Leigh Koetsier, Anna Sirico, Ada T. Agidi, Dario Antonini, Caterina Missero, Kathleen Janee Green · 2014 · Journal of Investigative Dermatology
52. Antitumor Action of a Novel Histone Deacetylase Inhibitor, YF479, in Breast Cancer
    Tao Zhang, Yihua Chen, Jingjie Li, Feifei Yang, Haigang Wu, Fujun Dai, Meichun Hu, Xiaoling Lü, Yi Peng, Mingyao Liu et al. · 2014 · Neoplasia
53. Histone deacetylase inhibitors: a patent review (2009 – 2011)
    Vincenzo Carafa, Marco Miceli, Lucia Altucci, Angela Nebbioso · 2012 · Expert Opinion on Therapeutic Patents
54. Collateral Sensitivity of Parthenolide via NF-κB and HIF-α Inhibition and Epigenetic Changes in Drug-Resistant Cancer Cell Lines
    Mona Dawood, Edna Ooko, Thomas Efferth · 2019 · Frontiers in Pharmacology
55. HDAC inhibitor-induced drug resistance involving ATP-binding cassette transporters (Review)
    Xuan Ni, Li Li, Guoyu Pan · 2014 · Oncology Letters
56. Marine-Derived Natural Lead Compound Disulfide-Linked Dimer Psammaplin A: Biological Activity and Structural Modification
    Qinxue Jing, Xu Hu, Yan-Zi Ma, Jiahui Mu, Weiwei Liu, Fanxing Xu, Zhan‐Lin Li, Jiao Bai, Huiming Hua, Dahong Li · 2019 · Marine Drugs
57. Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer
    Mingming Wei, Maodun Xie, Zhen Zhang, Yujiao Wei, Juan Zhang, Hongli Pan, Benlong Li, Jingjing Wang, Yang Song, Chuangke Chong et al. · 2020 · European Journal of Medicinal Chemistry
58. Extracellularly secreted APE1/Ref-1 triggers apoptosis in triple-negative breast cancer cells via RAGE binding, which is mediated through acetylation
    Yu Ran Lee, Ki Mo Kim, Byeong Hwa Jeon, Sunga Choi · 2015 · Oncotarget
59. The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines
    Maria Cosenza, Monica Civallero, Stefania Fiorcari, Samantha Pozzi, Luigi Marcheselli, Alessia Bari, Paola Ferri, Stefano Sacchi · 2016 · Cancer Biology & Therapy
60. Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma
    Aaron P. Havas, Kameron B. Rodrigues, Anvi Bhakta, Joseph Demirjian, Seongmin Hahn, Jack D. Tran, Margarethakay Scavello, Ana A. Tula-Sanchez, Yi Zeng, Monika Schmelz et al. · 2016 · Cancer Biology & Therapy
61. CBP/p300 Bromodomains Regulate Amyloid-like Protein Aggregation upon Aberrant Lysine Acetylation
    Heidi Olzscha, Oleg Fedorov, Benedikt Mathias Kessler, Stefan Knapp, Nicholas Barrie La Thangue · 2016 · Cell chemical biology
62. Recent Progress in Histone Deacetylase (HDAC) 1 Inhibitors as Anticancer Agent
    Preeti Patel, Simranpreet K. Wahan, S. Vishakha, Balak Das Kurmi, Ghanshyam Das Gupta, Harish Rajak, Vivek Asati · 2022 · Current Cancer Drug Targets
63. Aurones as histone deacetylase inhibitors: Identification of key features
    Vincent Zwick, Alkiviadis Orfefs Chatzivasileiou, Nathalie Deschamps, Marina Roussaki, Claudia Avello Simões‐Pires, Alessandra Nurisso, Iza Denis, Christophe Blanquart, Nadine Martinet, Pierre‐Alain Carrupt et al. · 2014 · Bioorganic & Medicinal Chemistry Letters
64. Global-scale profiling of differential expressed lysine acetylated proteins in colorectal cancer tumors and paired liver metastases
    Zhanlong Shen, Bo Wang, Jianyuan Luo, Kewei Jiang, Hui Zhang, Harri K. Mustonen, Pauli Antero Puolakkainen, Jun Zhu, Yingjiang Ye, Shan Wang · 2016 · Journal of Proteomics
65. Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids
    Rodrigo Mendoza‐Sanchez, David Cotnoir‐White, Justyna Kulpa, Isabel Jutras, Joshua Pottel, Nicolas Moitessier, Sylvie Mader, James L. Gleason · 2015 · Bioorganic & Medicinal Chemistry
66. Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy
    Adeleye Oluwatosin Adeshakin, Funmilayo Oladunni Adeshakin, Dehong Yan, Xiaochun Wan · 2022 · Frontiers in Immunology
67. Epigenetic mechanisms in chronic obstructive pulmonary disease.
    Zong Dd, Ouyang Ry, P Chen · 2015 · PubMed
68. Vorinostat Eliminates Multicellular Resistance of Mesothelioma 3D Spheroids via Restoration of Noxa Expression
    Dario Barbone, Priscilla Cheung, Sailaja Kumari Battula, Sara Busacca, Steven G. Gray, Daniel B. Longley, Raphael Bueno, David J. Sugarbaker, Dean Anthony Fennell, V. Courtney Broaddus · 2012 · PLoS ONE
69. Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy
    Zhuang Yang, Mingsheng Shen, Minghai Tang, Wanhua Zhang, Xue Jun Cui, Zihao Zhang, Heying Pei, Yong Li, Mengshi Hu, Peng Bai et al. · 2019 · European Journal of Medicinal Chemistry
70. Efficient synthesis and biological activity of Psammaplin A and its analogues as antitumor agents
    Suckchang Hong, Yoonho Shin, Myunggi Jung, Min Woo Ha, Yohan Park, Yeon‐Ju Lee, Jongheon Shin, Ki Bong Oh, Sang Kook Lee, Hyeung‐geun Park · 2015 · European Journal of Medicinal Chemistry
71. Endoplasmic Reticulum Stress Plays a Pivotal Role in Cell Death Mediated by the Pan-Deacetylase Inhibitor Panobinostat in Human Hepatocellular Cancer Cells
    Roberta Montalbano, Petra Waldegger, Karl Quint, Samir Jabari, Daniel Neureiter, Romana Illig, Matthias Ocker, Pietro Di Fazio · 2013 · Translational Oncology
72. HDAC2 regulates FoxO1 during RANKL-induced osteoclastogenesis
    Ce Dou, Nan Li, Ning Ding, Chuan Liu, Xiaochao Yang, Fei Kang, Zhen Cao, Hongyu Quan, Tianyong Hou, Jianzhong Xu et al. · 2016 · American Journal of Physiology-Cell Physiology
73. HDAC Inhibitors Induce BDNF Expression and Promote Neurite Outgrowth in Human Neural Progenitor Cells-Derived Neurons
    Amir Bagheri, Parham Habibzadeh, Seyedeh Fatemeh Razavipour, Claude‐Henry Volmar, Nancy T. Chee, Shaun P. Brothers, Claes Wahlestedt, Seyed Javad Mowla, Mohammad Ali Faghihi · 2019 · International Journal of Molecular Sciences
74. Trichostatin A induces apoptotic cell death of HeLa cells in a Bcl-2 and oxidative stress-dependent manner
    Bo Ra You, Woo Hyun Park · 2012 · International Journal of Oncology
75. Inhibition of NAMPT pathway by FK866 activates the function of p53 in HEK293T cells
    Basant Kumar Thakur, Tino Dittrich, Prakash Chandra, Annette Becker, Yannick Lippka, Divakarvel Selvakumar, Jan‐Henning Klusmann, Dirk Reinhardt, Karl Welte · 2012 · Biochemical and Biophysical Research Communications
76. Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo
    Han-Lin Huang, Hsueh‐Yun Lee, An-Chi Tsai, Chieh-Yu Peng, Mei-Jung Lai, Jing-Chi Wang, Shiow‐Lin Pan, Che‐Ming Teng, Jing‐Ping Liou · 2012 · PLoS ONE
77. Histone deacetylase 5 promotes the proliferation of glioma cells by upregulation of Notch 1
    Quan Liu, Jiemin Zheng, JIA-KANG CHEN, Xianlei Yan, Hongmou Chen, Weixia Nong, Heqing Huang · 2014 · Molecular Medicine Reports
78. Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer
    Yuting Liu, Yunli Tong, Xia Yang, Fangyuan Li, Liang Zheng, Wenqin Liu, Jinjun Wu, Rilan Ou, Guiyu Zhang, Ming Hu et al. · 2016 · Pharmacological Research
79. Expression of Histone Deacetylases in Diffuse Large B-cell Lymphoma and Its Clinical Significance
    Sung Hak Lee, Changyoung Yoo, Soyoung Im, Ji‐Han Jung, Hyun Joo Choi, Jinyoung Yoo · 2014 · International Journal of Medical Sciences
80. Oxazole-Bridged Combretastatin A-4 Derivatives with Tethered Hydroxamic Acids: Structure–Activity Relations of New Inhibitors of HDAC and/or Tubulin Function
    Florian Schmitt, Lisa Chiara Gosch, Alexandra Dittmer, Matthias Rothemund, Thomas Mueller, Rainer Schobert, Bernhard Biersack, Andrea Volkamer, Michael Höpfner · 2019 · International Journal of Molecular Sciences
81. Histone deacetylase 4 mediates SMAD family member 4 deacetylation and induces 5-fluorouracil resistance in breast cancer cells
    Seong‐Lan Yu, Dong Chul Lee, Ji Woong Son, Chang Gyo Park, Hoi Young Lee, Jaeku Kang · 2013 · Oncology Reports
82. Emerging role of epigenetics in systemic sclerosis pathogenesis
    Marzena Ciechomska, Jacob M. van Laar, Steven O’Reilly · 2014 · Genes and Immunity
83. Pharmacologic activation of autophagy without direct mTOR inhibition as a therapeutic strategy for treating dry macular degeneration
    Qitao Zhang, Feriel Presswalla, Robin R. Ali, David N. Zacks, Debra A. Thompson, Jason M. L. Miller · 2021 · Aging
84. Synthesis and biological evaluation of novel quinolone derivatives dual targeting histone deacetylase and tubulin polymerization as antiproliferative agents
    Xuan Wang, Xiaoye Jiang, Shiyou Sun, Yongqiong Liu · 2018 · RSC Advances
85. Teratogenic Activity of HDAC Inhibitors
    Erminio Giavini, Elena Menegola · 2014 · Current Pharmaceutical Design
86. Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo
    Yanxia Zhao, Dandan Yu, Hongge Wu, Hongli Liu, Hongxia Zhou, Runxia Gu, Ruiguang Zhang, Sheng Zhang, Gang Wu · 2013 · International Journal of Oncology
87. Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting
    Sunil Arani Reddy · 2016 · Critical Reviews in Oncology/Hematology
88. Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11
    David F. Tough, Huw D. Lewis, Inmaculada Rioja, Matthew J. Lindon, Rab K. Prinjha · 2014 · British Journal of Pharmacology
89. Discovery of decamidine as a new and potent PRMT1 inhibitor
    Jing Zhang, Kun Qian, Chunli Yan, Maomao He, Brenson A. Jassim, Ivaylo N. Ivanov, Yujun George Zheng · 2017 · MedChemComm
90. Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2
    Yu Yu, Dongzhi Ran, Junhao Jiang, Tao Pan, Yan Rong Dan, Qiang Tang, Wěi Li, Lin Zhang, Linling Gan, Zongjie Gan · 2019 · Bioorganic & Medicinal Chemistry Letters
91. A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma
    Belamy B. Cheung, Ane Kleynhans, Rituparna Mittra, Patrick Y. Kim, Jessica K. Holien, Zsuzsanna S. Nagy, Olivia C. Ciampa, Janith A. Seneviratne, Chelsea Mayoh, Mukesh Raipuria et al. · 2021 · Oncogene
92. Drugging the Schistosome Zinc-Dependent HDACs: Current Progress and Future Perspectives
    Martin Marek, Guilherme Oliveira, Raymond John Pierce, Manfred Jung, Wolfgang Sippl, Christophe Romier · 2015 · Future Medicinal Chemistry
93. Synergistic Radiosensitization by Gold Nanoparticles and the Histone Deacetylase Inhibitor SAHA in 2D and 3D Cancer Cell Cultures
    Nóra Igaz, Krisztina Szöke, Dávid Kovács, Andrea Buhala, Zoltán Varga, Péter Bélteky, Zsolt Rázga, László Tiszlavicz, Csaba Vízler, Katalin Hidéghety et al. · 2020 · Nanomaterials
94. The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma
    Claudia Andreu‐Vieyra, James R. Berenson · 2014 · Therapeutic Advances in Hematology
95. Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity
    Gabriele Riva, Valentina Butta, Chiara Cilibrasi, Simona Baronchelli, Serena Redaelli, Leda Dalprà, Marialuisa Lavitrano, Angela Bentivegna · 2016 · Oncology Reports
96. Histone Deacetylase Inhibitors: A Novel Therapeutic Weapon Αgainst Medullary Thyroid Cancer?
    Christos Damaskos, Serena I. Valsami, Eleftherios D Spartalis, Efstathios Antoniou, Periklis I. Tomos, Stefanos Karamaroudis, Theofano Zoumpou, Vasilios Pergialiotis, Konstantinos Stergios, Constantinos Michaelides et al. · 2016 · Anticancer Research
97. Pojamide: An HDAC3-Selective Ferrocene Analogue with Remarkably Enhanced Redox-Triggered Ferrocenium Activity in Cells
    Cory A. Ocasio, Supojjanee Sansook, Rhiannon N. Jones, Justin M. Roberts, Thomas G. Scott, Nikolaos Tsoureas, Peter Coxhead, Matthew Guille, Graham J. Tizzard, Simon John Coles et al. · 2017 · Organometallics
98. The chemopreventive activity of the histone deacetylase inhibitor tributyrin in colon carcinogenesis involves the induction of apoptosis and reduction of DNA damage
    Renato Heidor, Kelly Silva Furtado, Juliana Festa Ortega, Tiago Franco de Oliveira, Paulo Tavares, Alessandra Vieira, Mayara Lilian Paulino Miranda, Eduardo Purgatto, Fernando Salvador Moreno · 2014 · Toxicology and Applied Pharmacology
99. Temporal Phosphoproteome Dynamics Induced by an ATP Synthase Inhibitor Citreoviridin*
    Chia-Wei Hu, Chia‐Lang Hsu, Yu‐Chao Wang, Yasushi Ishihama, Wei‐Chi Ku, Hsuan‐Cheng Huang, Hsueh‐Fen Juan · 2015 · Molecular & Cellular Proteomics
100. Deleting HDAC3 rescues long-term memory impairments induced by disruption of the neuron-specific chromatin remodeling subunit BAF53b
     Guanhua Shu, Enikö A. Kramár, Alberto J. López, Grace Huynh, Marcelo A. Wood, Janine L. Kwapis · 2018 · Learning & Memory